Nicotine Replacement Therapy during Pregnancy and Child Health Outcomes: A Systematic Review

Julie Blanc, Barthélémy Tosello, Mikael O. Ekblad, Ivan Berlin and Antoine Netter
Additional contact information
Julie Blanc: Department of Obstetrics and Gynecology, North Hospital, APHM, Chemin des Bourrely, 13015 Marseille, France
Barthélémy Tosello: Department of Neonatology, North Hospital, Assistance Publique des Hôpitaux de Marseille, 13015 Marseille, France
Mikael O. Ekblad: Department of General Practice, Institute of Medicine, Turku University, Turku University Hospital, 20014 Turku, Finland
Ivan Berlin: Department of Pharmacology, Assistance Publique-Hôpitaux de Paris, Sorbonne University, 75013 Paris, France
Antoine Netter: Department of Obstetrics and Gynecology, North Hospital, APHM, Chemin des Bourrely, 13015 Marseille, France

IJERPH, 2021, vol. 18, issue 8, 1-11

Abstract: Tobacco smoking in pregnancy is a worldwide public health problem. A majority of pregnant smokers need assistance to stop smoking. Most scientific societies recommend nicotine replacement therapy (NRT) during pregnancy but this recommendation remains controversial because of the known fetal toxicity of nicotine. The objective of this systematic review was to provide an overview of human studies about child health outcomes associated with NRT use during pregnancy. The electronic databases MEDLINE, the Cochrane Database, Web of Science, and ClinicalTrials.gov were searched from the inception of each database until 26 December 2020. A total of 103 articles were identified through database searching using combination of keywords. Out of 75 screened articles and after removal of duplicates, ten full-text articles were assessed for eligibility and five were included in the qualitative synthesis. NRT prescription seems to be associated with higher risk of infantile colic at 6 months as in case of smoking during pregnancy, and with risk of attention-deficit/hyperactivity disorder. No association between NRT during pregnancy and other infant health disorders or major congenital anomalies has been reported. Well-designed controlled clinical trials with sufficient follows-up are needed to provide more information on the use of NRT or other pharmacotherapies for smoking cessation during pregnancy on post-natal child health outcomes.

Keywords: smoking cessation agents; tobacco use cessation devices; pregnancy; congenital abnormalities; child health; respiration disorders; attention deficit disorder with hyperactivity (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/8/4004/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/8/4004/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:8:p:4004-:d:533953

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().